# NCT06115642 (NCT06115642)

> A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06115642
- Phase: PHASE1
- Status: ENROLLING_BY_INVITATION
- Sponsor: Shanghai Henlius Biotech
- Conditions: Advanced/Metastatic Malignant Solid Tumors
- Interventions: HLX43; HLX10
- Enrollment: 367
- Primary outcome: The Dose-Limiting Toxicity (DLT) of HLX43 within 21 days after the first Administration
- Primary outcome: Objective response rate (ORR)
- Primary outcome: The maximum tolerated dose (MTD) of HLX43
- Primary outcome: RP2D

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06115642